lazertinib

Showing 2 posts of 2 posts found.

SMC accepts amivantamab and lazertinib for EGFR-positive lung cancer

May 22, 2026
SMC, amivantamab, lazertinib, lung cancer

The Scottish Medicines Consortium (SMC) has accepted Rybrevant (amivantamab) in combination with Lazcluze (lazertinib) for use within NHS Scotland as …

janssen_latest_logo_on_sign_closer

J&J buy global rights to Yuhan’s lazertinib in deal worth $1.2bn

November 6, 2018
Manufacturing and Production J&J, JJ, NSCLC, Yuhan, deal, lazertinib, south korea

Johnson & Johnson’s Janssen Biotech unit has bought the rights to Yuhan’s third-generation EGFR tyrosine kinase inhibitor (TKI) lazertinib in a deal …

The Gateway to Local Adoption Series

Latest content